About Cytosorbents Corp
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://cytosorbents.com/
Frequently Asked Questions
What is the 52-week range for CTSO?
The 52-week high is $20.4 and the 52-week low is $3.765.
What is the P/E ratio for CTSO?
The P/E ratio data is currently unavailable.
What is the dividend yield for CTSO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -165.13%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -48.94%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.80.
Analyst Recommendation Trends
Wall Street analyst consensus for CTSO over the last few months:
Latest CTSO News
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal from October 1
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share.
CytoSorbents Regains Nasdaq Compliance
CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14–16, 2026, in New York City. Dr. Phillip Chan, Chief Executive Officer and Peter Mariani, Chief Financial Officer of CytoSorbents will be attending the conference, joining Sean Lee, Vice Pr
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference,...
CytoSorbents Announces Reverse Stock Split
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock"). The Reverse Stock Split is expected to become effective on September 8, 2026, Eastern Time (the "Effective Time"), and the Common Stock is expected to
CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor
By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT New Findings Presented at European Society of Cardiology (ESC) Congress 2026 On September 2, 2026, the CytoSorbents (NASDAQ: CTSO) announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares increased by
Cytosorbents Announces 1-for-20 Reverse Stock Split, Effective September 8
Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price RequirementExpected to Become Effective and Trade on Split-Adjusted Basis at the Market
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Chan Phillip P. | +3,774 | $6 | $22,644 |
| 2026-09-15 | Sobel Alan D. | +100 | $6.01 | $601 |
| 2026-09-15 | Sobel Alan D. | +500 | $6.05 | $3,025 |
| 2026-09-15 | Sobel Alan D. | +1,900 | $6.12 | $11,628 |
| 2026-09-14 | Capponi Vincent | +273 | $5.9 | $1,611 |
| 2026-09-14 | Capponi Vincent | +1,800 | $6.07 | $10,926 |
| 2026-09-04 | Chan Phillip P. | +200,000 | $0.35 | $70,000 |
| 2026-06-15 | MARIANI PETER J | +100,000 | $0.44 | $44,000 |
| 2026-06-15 | Chan Phillip P. | +10,333 | $0.43 | $4,443 |
| 2026-06-12 | Chan Phillip P. | +251,136 | $0.4 | $100,454 |
| 2025-11-18 | Chan Phillip P. | +100,000 | $0.64 | $64,000 |